MINI FUTURE LONG - JAZZ PHARMACEUTICALS Share Price

Certificat

DE000MG3VEG6

Market Closed - Börse Stuttgart 19:57:02 14/06/2024 BST
1.93 EUR -2.53% Intraday chart for MINI FUTURE LONG - JAZZ PHARMACEUTICALS
Current month+45.11%
1 month+3.76%
Date Price Change
14/06/24 1.93 -2.53%
13/06/24 1.98 +6.45%
12/06/24 1.86 +5.68%
11/06/24 1.76 +4.76%
10/06/24 1.68 -15.58%

Delayed Quote Börse Stuttgart

Last update June 14, 2024 at 07:57 pm

More quotes

Static data

Product typeCertificat Turbo Stop Loss
Buy / SellCALL
Underlying JAZZ PHARMACEUTICALS PLC
Issuer Morgan Stanley
WKN MG3VEG
ISINDE000MG3VEG6
Date issued 08/05/2024
Strike 91.83 $
Maturity Unlimited
Parity 10 : 1
Emission price 1.76
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 2.06
Lowest since issue 1.11

Company Profile

Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).
Sector
-
More about the company

Ratings for Jazz Pharmaceuticals plc

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Jazz Pharmaceuticals plc

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
112.9 USD
Average target price
180.3 USD
Spread / Average Target
+59.65%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW